BLINATUMOMAB
Clinical trials for BLINATUMOMAB explained in plain language.
Never miss a new study
Get alerted when new BLINATUMOMAB trials appear
Sign up with your email to follow new studies for BLINATUMOMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo tackles tough leukemia in early trial
Disease control Not yet recruitingThis early-phase study tests the safety of combining two drugs, blinatumomab and revumenib, for adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a KMT2A gene change. The trial will enroll 20 people, including those whose cancer has returned or…
Matched conditions: BLINATUMOMAB
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:00 UTC
-
Under-the-skin shot aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis study tests whether giving blinatumomab as a shot under the skin can safely control small amounts of leftover leukemia (measurable residual disease) in adults with B-cell acute lymphoblastic leukemia. About 40 participants will receive the drug to see if it prevents the canc…
Matched conditions: BLINATUMOMAB
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:46 UTC
-
New combo shot and pill aims to tame tough leukemia
Disease control Not yet recruitingThis study tests whether giving two drugs together—blinatumomab as a shot under the skin and olverembatinib as a pill—can help control a fast-growing blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). About 60 adults with newly diagnosed or r…
Matched conditions: BLINATUMOMAB
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC